DELTA-FLY PHARMA, INC.

Other languages Delta-Fly Pharma, Inc.

Equities

4598

JP3549370009

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-06-18 am EDT			5-day change	1st Jan Change
572 ^JPY	+1.60%		+3.81%	-43.65%

Apr. 08	Delta-Fly Pharma Inc. Receives Notice of Authorization to Conduct the Phase I/II Study of DFP-10917 Combined with Venetoclax	CI
Mar. 11	Delta-Fly Pharma Inc. Announces FDA Submission of the Protocol of the Phase I/II Study of DFP-10917 Combined with Venetoclax in the AML Patients Treated by VTX in the AML	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Delta-Fly Pharma Inc.: Mitteilung der Zulassung der Phase I/II-Studie zu DFP-10917 in Kombination mit Venetoclax	Apr. 08
Delta-Fly Pharma Inc. Receives Notice of Authorization to Conduct the Phase I/II Study of DFP-10917 Combined with Venetoclax	Apr. 08
Delta-Fly Pharma Inc.: FDA-Einreichung des Protokolls der Phase I/II-Studie von DFP-10917 in Kombination mit Venetoclax (VTX) bei AML-Patienten, die mit VTX vorbehandelt wurden, umfasste ein Regime	Mar. 11
Delta-Fly Pharma Inc. Announces FDA Submission of the Protocol of the Phase I/II Study of DFP-10917 Combined with Venetoclax in the AML Patients Treated by VTX in the AML	Mar. 11
Delta-Fly Pharma Inc.: Einreichung von Abstracts für klinische Phase I-Studie von DFP-14927 für die ASCO-Jahresversammlung 2024	Feb. 07
Delta-Fly Pharma Inc. Announces Abstracts Submission for Phase I Clinical Trial of DFP-14927 to 2024 ASCO Annual Meeting	Feb. 07
Delta-Fly Pharma Inc.: Bekanntmachung des Beginns einer klinischen Phase-III-Vergleichsstudie mit DFP-14323	Feb. 02
Delta-Fly Pharma Inc Announces Initiation of Phase III Pivotal Comparative Clinical Trial of DFP-14323	Feb. 02
Delta-Fly Pharma, Inc. Provides Update on Interim Analysis Status of Phase III Study of DFP-10917 in Patients with R/R AML	Jan. 30
Delta-Fly Pharma Inc.: Aktueller Stand der Forschung und Entwicklung von DFP-10917 und DFP-14927, einem neuartigen PEG-Wirkstoffkonjugat für Patienten mit R/R AML	Jan. 05
Delta-Fly Pharma Inc.: Zeitplan für die Zwischenanalyse der Phase-3-Studie von DFP-10917 bei rezidivierter/refraktärer akuter myeloischer Leukämie (R/R AML)	23-06-30
Delta-Fly Pharma, Inc. erhält von der US Food and Drug Administration die Orphan Drug Designation für DFP-10917	22-12-07

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Secure and Increase the Performance of your Investments with our Team of Experts at your Side

Securing my Investments

fermer